Bio-Rad Acquisition of Ciphergen's Tools Business Delayed | GenomeWeb
NEW YORK (GenomeWeb News) — Ciphergen’s sale of its proteomics tools business to Bio-Rad did not close on Nov. 1 as originally expected.
 
After Ciphergen’s shareholders approved the sale last week the company said it expected the transaction to close before Nov. 1. But as of yesterday the deal had not closed.
 
A Bio-Rad spokeswoman declined to comment on the delay but said Wednesday that the deal could be finished within the next few days.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In PNAS this week: carbapenem resistance in Enterobacteriaceae, selection against educational attainment-linked variants, and more.

Technology Review points out that a new US presidential science advisor hasn't been selected.

Researchers find that blood tests might be able to help determine severity of a concussion, Wired reports.

President-elect Donald Trump considers other candidates for director of the National Institutes of Health, Nature News reports.